ATAI Stock Analysis: Buy, Sell, or Hold?
ATAI - ATAI Life Sciences N.V. Common Shares
$5.43
0.46 (9.15%)
▲
5d:
+4.53%
30d:
+42.76%
90d:
+43.14%
BUY
HIGH Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 13, 2026
29d
Smart Money Distribution
None View Scanner →
Strength: 7.5/10
Get Alerted When ATAI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
10 traders called ATAI this week
83% bullish • 2 bearish
83% bullish • 2 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: ATAI shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
✅ BUY SIGNAL: ATAI shows strong fundamentals and good volume confirmation. Solid entry point despite slightly high pricing.
In-depth Analysis How we analyze
Valuation Analysis: ATAI is currently trading at $5.42, which is considered slightly high relative to its 30-day fair value range of $3.93 to $5.10.
Technical Outlook: Technically, ATAI is in a strong uptrend. The price is approaching resistance at $5.52. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 9.2% recently.
Market Sentiment: ATAI has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $14.17 (+185.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ATAI is in a strong uptrend. The price is approaching resistance at $5.52. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 9.2% recently.
Market Sentiment: ATAI has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $14.17 (+185.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$3.93 -
$5.10
Company Quality Score
63/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
84.2%
All Signals
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+9.2%)
- BULLISH: Trading 185.0% below Wall St target ($14.17)
Trading Range Analysis
30-Day Trading Range
$3.93 -
$5.10
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$4.77
Resistance Level
$5.52
Current Trend
Strong Uptrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-11.02
Wall Street Target
$14.17
(+185.0%)
Revenue Growth (YoY)
-38.7%
Earnings Growth (YoY)
-96.8%
Share & Embed Analysis
Last updated: July 14, 2026 10:42 AM ET
Data refreshes hourly during market hours. Next update: 11:42 AM
Data refreshes hourly during market hours. Next update: 11:42 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ATAI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Kevin James Craig
SELL
42579 shares
2026-04-20
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 62 BUY |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$258 | 67 BUY |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$36 | 61 BUY |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$128 | 59 HOLD |
|
BEAM
Beam Therapeutics Inc |
STRONG BUY
17 analysts |
$51 | 49 HOLD |
